Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Rimini M, et al. Among authors: rapposelli ig. Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. Liver Int. 2023. PMID: 37452505
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.
Sala G, Rapposelli IG, Ghasemi R, Piccolo E, Traini S, Capone E, Rossi C, Pelliccia A, Di Risio A, D'Egidio M, Tinari N, Muraro R, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO). Sala G, et al. Among authors: rapposelli ig. Transl Oncol. 2013 Dec 1;6(6):676-84. doi: 10.1593/tlo.13475. eCollection 2013 Dec 1. Transl Oncol. 2013. PMID: 24466370 Free PMC article.
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.
Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, Melisi D, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Peretti U, et al. Among authors: rapposelli ig. ESMO Open. 2021 Feb;6(1):100032. doi: 10.1016/j.esmoop.2020.100032. Epub 2021 Jan 4. ESMO Open. 2021. PMID: 33399070 Free PMC article.
Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis.
Rapposelli IG, De Matteis S, Lanuti P, Valgiusti M, Bartolini G, Ulivi P, Marisi G, Pedica F, Burgio V, Frassineti GL, Cascinu S, Casadei-Gardini A. Rapposelli IG, et al. Cancers (Basel). 2021 Jan 8;13(2):213. doi: 10.3390/cancers13020213. Cancers (Basel). 2021. PMID: 33430142 Free PMC article.
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.
Casadei-Gardini A, Filippi R, Rimini M, Rapposelli IG, Fornaro L, Silvestris N, Aldrighetti L, Aimar G, Rovesti G, Bartolini G, Vivaldi C, Brunetti O, Sperti E, La Face R, Ratti F, Andrikou K, Valgiusti M, Bernardini L, Argentiero A, Fenocchio E, Frassineti GL, Cesario S, Giovannelli F, Quarà V, Leone F, Cascinu S. Casadei-Gardini A, et al. Among authors: rapposelli ig. Oncology. 2021;99(5):292-299. doi: 10.1159/000512796. Epub 2021 Feb 24. Oncology. 2021. PMID: 33626532
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: rapposelli ig. Target Oncol. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1. Target Oncol. 2021. PMID: 33646487
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: rapposelli ig. Target Oncol. 2021 May;16(3):411-412. doi: 10.1007/s11523-021-00808-3. Target Oncol. 2021. PMID: 33738697 No abstract available.
39 results